Fouad Husnain, MD
Critical Care Medicine · Burlington, WINPI 1295899854
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,534 of the $3,595 with a category attached, or 70.5%. 19 manufacturers reported payments, led by Intuitive Surgical at 26.2% of the total.
Across 86 payments — averaging $41.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$942
- AstraZeneca$810
- GSK$542
- Boehringer Ingelheim$301
- Sanofi$259
- Insmed, Inc.$240
- plus $499 from 13 others
What the payments were for
- Travel & lodging$83623%
- Food & beverage$2,53470%
- Education$2256%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 5 | $942 |
| AstraZeneca | 28 | $810 |
| GSK | 22 | $542 |
| Boehringer Ingelheim | 7 | $301 |
| Sanofi | 4 | $259 |
| Insmed, Inc. | 3 | $240 |
| Harmony Biosciences LLC | 2 | $108 |
| Galvanize Therapeutics, Inc | 1 | $103 |
| United Therapeutics Corporation | 3 | $74 |
| Avadel CNS Pharmaceuticals, LLC | 2 | $48 |
| Grifols USA, LLC | 1 | $29 |
| Lilly USA, LLC | 1 | $22 |
| Amgen | 1 | $21 |
| Regeneron Healthcare Solutions, Inc. | 1 | $20 |
| Jazz Pharmaceuticals Inc. | 1 | $16 |
| Covis Pharma GmbH | 1 | $16 |
| Vanda Pharmaceuticals Inc. | 1 | $16 |
| Merck | 1 | $14 |
| Sanofi-aventis U.S. LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$817
- TRELEGY ELLIPTA$125
- Arikayce$125
- DUPIXENT$125
- NUCALA$125
- BREZTRI$113
- OFEV$106
- ALIYA SYSTEM$103
How this compares
$3,595 in reported general payments places this provider in the 85th percentile of 108 critical care medicine providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 565 | $474,393 |
| XywavSodium,calcium,mag,pot Oxybate | 12 | $320,129 |
| OfevNintedanib Esylate | 19 | $261,542 |
| NucalaMepolizumab | 15 | $118,205 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 146 | $96,199 |
| Dupixent PenDupilumab | 19 | $80,044 |
| Breo ElliptaFluticasone/Vilanterol | 145 | $71,296 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 85 | $68,193 |
| SunosiSolriamfetol Hcl | 30 | $27,412 |
| Spiriva RespimatTiotropium Bromide | 23 | $17,746 |
| Roflumilast | 107 | $12,128 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 14 | $10,278 |
| Incruse ElliptaUmeclidinium Bromide | 17 | $8,450 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 238 | $7,155 |
| Advair HfaFluticasone Propion/Salmeterol | 14 | $5,572 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Nucala, Anoro Ellipta, Breo Ellipta, Incruse Ellipta | $542 | $768,544888 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $301 | $289,56656 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $810 | $73,377100 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 108 critical care medicine providers in Wisconsin.
Other critical care medicine in Burlington
- Jennifer RobertsMarshfield$15K
- Mrigank GuptaMilwaukee$10K
- Sangita Goella Crosse$7K
- Bijan NezamiSummit$5K
- Abdullah Al TwalMarshfield$5K
- Amit TanejaMilwaukee$5K
- Brian GriffithMadison$4K
- Weston AndrewsBrookfield$4K
- Frank BrodkeyJanesville$4K
- Pierre KoryMilwaukee$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.